エドガーで原本を確認する
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Lynn Baxter
|
|
|
b)
|
Position/status
|
President, Europe
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Julie Brown
|
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
James Ford
|
|
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
David Redfern
|
|
|
b)
|
Position/status
|
President,
Corporate Development
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Regis Simard
|
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Philip Thomson
|
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Deborah Waterhouse
|
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Victoria Whyte
|
|
|
b)
|
Position/status
|
SVP
& Company Secretary
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
6 (partnership shares)
|
||
|
£19.3496
|
6 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
12 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||
|
a)
|
Name
|
Neil Falkingham
|
|
|
b)
|
Position/status
|
PCA of Lynn Baxter (President, Europe)
|
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
|
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company’s Share
Reward Plan
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£19.3496
|
7 (partnership shares)
|
||
|
£19.3496
|
7 (matching shares)
|
||
|
d)
|
Aggregated
information
|
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£19.3496
|
||
|
e)
|
Date
of the transaction
|
2026-08-11
|
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
13, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|